Biotech startup Airna raises $60M for RNA editing medicines
Bio Pharma Dive
JULY 31, 2024
Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.
Wed.Jul 31, 2024
298 
Pfizer’s Q2 2024 net income attributable to shareholders down 98%
Pharmaceutical Technology
JULY 31, 2024
Pfizer has posted a 98% decrease in net income attributable to shareholders of $41m for Q2 2024, compared to $2.3bn in Q2 2023.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GSK cuts vaccine forecasts, while predicting faster overall growth
Bio Pharma Dive
JULY 31, 2024
Several factors are slowing U.S. sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers.
One Diet Choice While Pregnant May Protect Your Child’s Heart For Life
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 31, 2024
The food consumed by a pregnant mother just got a little bit more important. According to a new study on pregnant mice, a diet rich in fiber improves the long-term heart health of developing offspring, significantly lowering their risk of cardiovascular disease later in life.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Magazine: Left in limbo: when pharma halts rare disease research
Pharmaceutical Technology
JULY 31, 2024
Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.
Merck shares slide as Gardasil sales drop in China
Bio Pharma Dive
JULY 31, 2024
The unexpected disclosure in Merck’s second quarter earnings prompted an investor sell-off that some analysts say may be overblown.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
ICMR calls for proposals to commercialize CRISPR Cas-Based TB detection system
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 31, 2024
The Indian Council of Medical Research (ICMR) has announced an Expression of Interest (EoI) inviting eligible organizations, companies, and manufacturers to participate in the ‘Transfer of Technology’ for a CRISPR Cas-based TB detection system.
FDA approves J&J’s multiple myeloma therapy
Pharmaceutical Technology
JULY 31, 2024
The US FDA has granted approval for Johnson & Johnson’s (J&J) DARZALEX FASPRO for treating newly diagnosed multiple myeloma (NDMM).
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Bio Pharma Dive
JULY 31, 2024
Elsewhere, Fibrogen plans to lay off three-quarters of its U.S. staff, while gene editing specialist Intellia is now cleared to start a U.K. study focused on AAT deficiency.
Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year
Pharmaceutical Technology
JULY 31, 2024
The FDA has set a PDUFA target action date of 30 January 2025 for Vertex’s acute pain treatment therapy that is a non-opioid alternative.
July 31, 2024: Gene Editing Therapies and Population Health, in This Week’s PCT Grand Rounds
Rethinking Clinical Trials
JULY 31, 2024
Dr. Adrian Hernandez In this Friday’s PCT Grand Rounds, Adrian Hernandez of Duke University will present “Precision Health to Population Health: Opportunities and Challenges for Gene Editing Therapies.” The Grand Rounds session will be held on Friday, August 2, 2024, at 1:00 pm eastern. Hernandez is a professor of medicine and vice dean in the Duke University School of Medicine and the executive director of the Duke Clinical Research Institute.
Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023
Pharmaceutical Technology
JULY 31, 2024
The biopharmaceutical industry experienced varied revenue shifts in 2023, with significant success for companies with obesity drugs.
Bayer lops off 70 more employees at New Jersey headquarters
Fierce Pharma
JULY 31, 2024
Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more workers at the site. | Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more at the site, according to a state Worker Adjustment and Retraining Notification.
Imunon’s shares soar after IL-12 therapy success in Phase II trial
Pharmaceutical Technology
JULY 31, 2024
In the intent-to-treat cohort, IMNN-001 plus chemotherapy offered a median 11.1-month increase in overall survival versus chemotherapy alone.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
EPSRC launches two new hubs to transform early disease diagnosis in the UK
Pharma Times
JULY 31, 2024
Quantum-based technologies will explore infectious diseases, cancer and dementia
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
Pharmaceutical Technology
JULY 31, 2024
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
Apollo and Oxford University enter drug discovery and development collaboration
Pharma Times
JULY 31, 2024
The latest collaboration marks Apollo’s sixth agreement with a research institution
Novo faces growth challenges despite GLP-1 receptor agonist obesity boom
Pharmaceutical Technology
JULY 31, 2024
The industry is seeking to scale up and satisfy demand for diabetes and obesity treatments that are now chronically in shortage.
Frontiers Health 2024: Connecting changemakers, cultivating health system change
pharmaphorum
JULY 31, 2024
Frontiers Health 2024 is a platform connecting innovators and changemakers in the life sciences industry to cultivate positive changes in health systems. Discover the latest trends and insights in healthcare innovation.
Leveragen and Moderna link to advance therapeutics
Pharmaceutical Technology
JULY 31, 2024
Leveragen and Moderna have entered a research, option and licence agreement to advance the development of various therapeutics.
Vertex eyes FDA decision on non-opioid pain drug in January
pharmaphorum
JULY 31, 2024
Vertex has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year
FDA drug application costs set to rise to $4.3m from October
Pharmaceutical Technology
JULY 31, 2024
The US Food and Drug Administration application fees have increased by around $300,000 from 2024 and by $2 million compared to a decade ago.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
J&J touts new 'foundational' frontline multiple myeloma treatment as Darzalex Faspro nabs quadruplet FDA nod
Fierce Pharma
JULY 31, 2024
On the heels of game-changing trial results presented at la | On the heels of game-changing trial results presented at last year's ASH meeting, J&J is introducing what it calls a "foundational frontline therapy" in multiple myeloma and at the same time expanding its already impressive presence in the field.
Patients resist Novo Nordisk plan to stop making Levemir
pharmaphorum
JULY 31, 2024
Patient advocacy group APIC has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir
Amgen in internet of things: theme innovation strategy
Pharmaceutical Technology
JULY 31, 2024
How many patents did Amgen submit related to internet of things last quarter, and how many were granted? Discover the latest information here.
How biometrics applications are contributing to clinical trial diversity
pharmaphorum
JULY 31, 2024
Ensuring equitable access to medications remains a fundamental commitment for many pharmaceutical companies to their customers, patients, and stakeholders. However, there has been a discernible shift recently in the timing of access discussions.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Lundbeck leaves Trintellix to partner Takeda in the US, opting for royalties as it focuses efforts on Rexulti
Fierce Pharma
JULY 31, 2024
The end of an era is nearing for Lundbeck. After a 17-year collaboration with Takeda on depression drug Trintellix, the Danish drugmaker is passing over its U.S. rights to its partner. | Lundbeck will collect only royalties on Takeda's U.S. sales of the partners' depression med as it reallocates resources to other growth drivers such as antipsychotic Rexulti.
GSK raises forecasts for 2024, but shares slide
pharmaphorum
JULY 31, 2024
GSK raises 2024 forecasts on a strong Q2 led by HIV and cancer drugs, but its shares weakened on litigation concerns and weaker vaccine expectations
Teva rides growth momentum through Q2, boosts '24 sales outlook
Fierce Pharma
JULY 31, 2024
Teva and its long-term investors have been through much disappointment over the last decade, but 2024 is bringing optim | Teva has boosted its revenue and profit outlook for the year after reporting a strong quarter for its generics business. The company's key growth driver Austedo contributed to the performance, as well.
After EU setback, Eisai/Biogen build case for Leqembi
pharmaphorum
JULY 31, 2024
Eisai, Biogen report data showing benefit of Alzheimer's disease therapy Leqembi builds with time, with no increase in safety risk
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content